Targeting ferroptosis: a novel pathway in oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
- PMID: 40227310
- DOI: 10.1007/s00210-025-04142-7
Targeting ferroptosis: a novel pathway in oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
Abstract
Malignancies of the oral cavity, oropharynx, hypopharynx, and larynx rank as the seventh most prevalent cancers globally, characterized by high morbidity and mortality. Despite advancements in conventional therapies, these cancers often demonstrate recurrence and treatment resistance. This review investigates ferroptosis, an iron-dependent regulated cell death mechanism, as a novel therapeutic target to overcome resistance and recurrence in these cancers. A narrative review study was conducted using online databases, including PubMed, Google Scholar, Scopus, and Web of Science. The search incorporated keywords such as "ferroptosis", "oral squamous cell carcinoma", "oropharyngeal cancer", "hypopharyngeal cancer", "laryngeal cancer", "iron metabolism", and "lipid peroxidation". Studies focusing on molecular mechanisms, ferroptosis regulation, and therapeutic applications were included. Key findings highlighted the involvement of genes like CA9, CAV1, and SLC7 A11 in oral squamous cell carcinoma (OSCC), contributing to progression and resistance. Ferroptosis inducers such as resveratrol and quercetin effectively promoted ferroptosis in OSCC by targeting pathways like p53/SLC7 A11. In hypopharyngeal and oropharyngeal cancers, agents like ascorbic acid and RSL3 enhanced lipid peroxidation, while laryngeal cancers showed resistance through molecules like SLC3 A2 and KPNA2, which could be counteracted with targeted therapies. Nanotechnology-based approaches, including photodynamic therapy and nanofiber membranes, offer potential for localized and effective ferroptosis induction. Ferroptosis holds promise as a therapeutic strategy for treating head and neck cancers by addressing treatment resistance and recurrence. Future research should focus on optimizing combination therapies, understanding molecular heterogeneity, and translating preclinical findings into clinical applications to improve patient outcomes.
Keywords: Ferroptosis; Head and neck cancer; Hypopharyngeal caner; Laryngeal cancer; Oral squamous cell carcinoma.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Research progress on ferroptosis in head and neck squamous cell carcinoma.J Mol Histol. 2025 Mar 17;56(2):109. doi: 10.1007/s10735-025-10381-y. J Mol Histol. 2025. PMID: 40095205 Review.
-
Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma.Front Pharmacol. 2024 Apr 22;15:1402514. doi: 10.3389/fphar.2024.1402514. eCollection 2024. Front Pharmacol. 2024. PMID: 38711989 Free PMC article. Review.
-
Combination treatment with ferroptosis and autophagy inducers significantly inhibit the proliferation and migration of oral squamous cell carcinoma.Biochem Biophys Res Commun. 2024 May 21;709:149842. doi: 10.1016/j.bbrc.2024.149842. Epub 2024 Mar 27. Biochem Biophys Res Commun. 2024. PMID: 38554601
-
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma.Cancers (Basel). 2025 Feb 5;17(3):530. doi: 10.3390/cancers17030530. Cancers (Basel). 2025. PMID: 39941896 Free PMC article.
-
Low-Concentration PTX And RSL3 Inhibits Tumor Cell Growth Synergistically By Inducing Ferroptosis In Mutant p53 Hypopharyngeal Squamous Carcinoma.Cancer Manag Res. 2019 Nov 20;11:9783-9792. doi: 10.2147/CMAR.S217944. eCollection 2019. Cancer Manag Res. 2019. PMID: 31819616 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous